Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 7/20 | 0.37 |
| ▸ | CA2 | P00918 | 7/20 | 0.37 |
| ▸ | CA12 | O43570 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 5/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7417687 | 0.88 | ITGB3 (0.43) | ITGB3ITGA2BCA1CA2CA12 | |
| SCHEMBL7408405 | 0.83 | ITGB3 (0.53) | ITGB3ITGA2BBCL2 | |
| SCHEMBL7407517 | 0.82 | ITGB3 (0.50) | ITGB3ITGA2BCA1CA2CA12 | |
| SCHEMBL1541948 | 0.78 | ITGB3 (0.59) | ITGB3ITGA2BCA1CA2CA12 | |
| SCHEMBL16940459 | 0.77 | ITGB3 (0.51) | ITGB3ITGA2BLTA4HACACB | |
| SCHEMBL30149840 | 0.76 | CA12 (0.60) | ITGB3ITGA2BCA1CA2CA12 | |
| SCHEMBL6871466 | 0.74 | ITGB3 (0.51) | ITGB3ITGA2BLTA4HPPARG | |
| SCHEMBL7358634 | 0.73 | ACACB (0.50) | ITGB3ITGA2BLTA4HPPARGPPARD | |
| SCHEMBL14131858 | 0.73 | CA1 (0.33) | CA1CA2CA12CA9 | |
| SCHEMBL15149719 | 0.73 | CA12 (0.42) | ITGB3ITGA2BCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6344484-B1 | TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | disclosed |
| EP-1159262-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000047552-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |